Characterizing genetic profiles in advanced non-small cell lung cancer using liquid biopsies

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to analyze the genetic profiles of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) through the use of liquid biopsies. By identifying molecular abnormalities in the plasma, the study seeks to provide a non-invasive method for detecting genetic alterations that can inform treatment decisions. The research focuses on patients who may not be eligible for traditional tissue biopsies and aims to enhance understanding of disease progression and treatment resistance. The findings could lead to better-targeted therapies for patients with specific genetic mutations.

Why it matters

Who can join: the full rules

COHORT 1

Inclusion Criteria:

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status
* Inclusion at the time of diagnostic
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

Exclusion Criteria:

\- Patients treated before their liquid biopsy

COHORT 2 Inclusion criteria

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement.
* Inclusion at the time of diagnosis
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

COHORT 3 Inclusion criteria

* Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status.
* Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)
* Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
* Age ≥ 18 years
* Covered by a health insurance
* Signed consent

Exclusion criteria

\- Initiation of immunotherpy before their liquid biopsy

Where it's running

• Centre Léon Bérard
  Lyon, France Recruiting
• Centre Hospitalier Annecy Genevois
  Annecy, France Active not recruiting
• CH Fleyriat
  Bourg-en-Bresse, France Active not recruiting
• Hôpital Louis Pradel
  Bron, France Active not recruiting
• CHU Grenoble Alpes
  Grenoble, France Active not recruiting
• CHRU de Saint-Etienne
  Saint-Priest-en-Jarez, France Active not recruiting

Study contacts

• Study coordinator: Pierre Saintigny, MD, PhD
• Email: pierre.saintigny@lyon.unicancer.fr

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Amivantamab with Lazertinib or Chemotherapy before surgery in EGFR-mutated NSCLC

  This study tests whether giving amivantamab together with lazertinib or with carboplatin and pemetrexed before surgery can slow or stop tumor growth in people with resectable EGFR-mutated NSCLC.

  Recruiting at 27 sites Phase 2 Janssen Research & Development, LLC · Duarte, California and 26 other locations · NCT07586202

• Multidisciplinary treatment planning for older people with lung cancer

  We will test a team-based approach that uses geriatric assessments to create personalized treatment plans for people aged 60–90 with newly diagnosed lung cancer to see if it improves 3-year progression-free survival compared with past patients.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07509333

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• Intratumoral injection of N17350 in advanced solid tumors

  Aims to see if injected N17350 can shrink or control tumors in adults with advanced solid cancers who have few other options.

  Recruiting at 7 sites Phase 1/2 Onchilles Pharma Inc · Los Angeles, California and 8 other locations · NCT07339176

• Clinical outcomes of amivantamab-based treatment for advanced EGFR-mutated non-small cell lung cancer in everyday care.

  This project will see how amivantamab-containing treatments work for people with advanced non-small cell lung cancer who have common EGFR mutations.

  Recruiting at 90 sites Janssen Research & Development, LLC · Graz and 89 other locations · NCT07230691

• PF-08634404 combined with other cancer medicines for advanced non-small cell lung cancer

  This will test whether PF-08634404 given with other cancer medicines is safe and can help adults with advanced or metastatic non-small cell lung cancer.

  Recruiting at 85 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 103 other locations · NCT07227298

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.